Multi-Specific Antibody Platform
Tri-specific antibody systems for precision targeting, immune recruitment, and viral escape prevention.
The problem we are solving.
A conventional antibody sees one target. This is often not enough. Infected cells display multiple markers, tumors mutate to hide single epitopes, and viruses escape single-antibody therapies through predictable evolutionary pressure.
Tri-specific antibodies solve this by binding three targets at once — typically the diseased cell, an immune effector, and a safety checkpoint. The result is a single molecule that identifies the problem, summons the solution, and holds both in productive proximity until the work is done.
How we tackle it.
MACRO HRD's antibody platform engineers tri-specific constructs de novo, selecting each of the three binding domains for a specific role: recognition of the disease marker, recruitment of a CD4, CD8, or NK effector cell, and prevention of escape through a conserved-epitope anchor.
The resulting molecules are small enough to reach dense tissue environments, stable enough for room-temperature storage, and programmable across indications. A tri-specific backbone validated for one disease can be re-armed with new binding domains within months.
Critically, every construct is engineered against the field's known safety failure modes. Immune-engaging therapies carry well-documented risks — cytokine-release and neurotoxicity among them — and decades of clinical experience have shown that unconstrained immune activation is dangerous. MACRO HRD's designs favor conditional, target-dependent activation, prioritizing a controllable safety profile alongside potency.
What makes this real.
Part of an integrated platform.
“Three points of contact are harder to escape than one. We design antibodies the virus cannot outrun.”